Big pharma, Partnering, Pharma

Boehringer Ingelheim big pharma deals Athera Biotech for novel cardiovascular antibody option agreement

Posted on 20 June 2013

Tags: , , ,

Athera Biotechnologies has entered into pharma deals involving an option agreement with Boehringer Ingelheim on a novel preclinical antibody program.

As part of the pharma deals, Athera grants to Boehringer Ingelheim, a big pharma, an exclusive option to acquire the entire cardiovascular antibody program.

Karolinska Development AB owns 65% of Athera Biotechnologies AB.

Athera’s fully-human monoclonal antibody is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death.

Pursuant to the terms of the pharma deals option agreement, Athera will conduct defined preclinical development and a Phase I study for the lead antibody and, following the completion of such study, Boehringer Ingelheim will have an exclusive option to acquire substantially all of Athera’s assets and rights relating to the program.

In exchange for Athera’s granting of the option in the pharma deals, Boehringer Ingelheim will pay an option fee.

The size of the fee and the other terms of the option are not being disclosed but this transaction is in line with market average terms for programs at similar stages of development.

Related 

Report: Cardiovascular Partnering Terms and Agreements

Report: Partnering Deals and Alliances with Boehringer Ingelheim

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply